<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ro">
	<id>https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=AveXis%2C_Inc.</id>
	<title>AveXis, Inc. - Revizia istoricului</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=AveXis%2C_Inc."/>
	<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=AveXis,_Inc.&amp;action=history"/>
	<updated>2026-05-02T12:28:24Z</updated>
	<subtitle>Istoricul versiunilor pentru această pagină din wiki</subtitle>
	<generator>MediaWiki 1.39.2</generator>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=AveXis,_Inc.&amp;diff=447369&amp;oldid=prev</id>
		<title>127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=AveXis,_Inc.&amp;diff=447369&amp;oldid=prev"/>
		<updated>2024-09-29T10:20:24Z</updated>

		<summary type="html">&lt;p&gt;The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;ro&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Versiunea anterioară&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Versiunea de la data 29 septembrie 2024 13:20&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l2&quot;&gt;Linia 2:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linia 2:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Descriere companie==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Descriere companie==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Novartis Gene Therapies, Inc. (https://www.novartis.com/), a gene therapy biotech company, develops treatments for rare and life-threatening genetic diseases. The company focuses on developing gene therapy product candidates for the treatment of type 1 spinal muscular atrophy, an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weakness. It offers AVXS-101, a AveXis’ gene therapy for the treatment of spinal muscular atrophy SMA Type 1, which is in Phase 1 clinical trial. Novartis Gene Therapies, Inc. was formerly known as AveXis, Inc., and changed its name in September 2020. The company was founded in 2010 and is based in Bannockburn, Illinois. AveXis, Inc. operates as a subsidiary of Novartis AG.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Novartis Gene Therapies, Inc. (https://www.novartis.com/), a gene therapy biotech company, develops treatments for rare and life-threatening genetic diseases. The company focuses on developing gene therapy product candidates for the treatment of type 1 spinal muscular atrophy, an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weakness. It offers AVXS-101, a AveXis’ gene therapy for the treatment of spinal muscular atrophy SMA Type 1, which is in Phase 1 clinical trial. Novartis Gene Therapies, Inc. was formerly known as AveXis, Inc., and changed its name in September 2020. The company was founded in 2010 and is based in Bannockburn, Illinois. AveXis, Inc. operates as a subsidiary of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[&lt;/ins&gt;Novartis AG&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;]]&lt;/ins&gt;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Grafic actiuni companie==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Grafic actiuni companie==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key tradeville_wiki:diff::1.12:old-408279:rev-447369 --&gt;
&lt;/table&gt;</summary>
		<author><name>127.0.0.1</name></author>
	</entry>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=AveXis,_Inc.&amp;diff=408279&amp;oldid=prev</id>
		<title>Admin: Pagină nouă: Pagina dedicata companiei AveXis, Inc. listata cu simbolul US.AVXS  ==Descriere companie== Novartis Gene Therapies, Inc. (https://www.novartis.com/), a gene therapy biotech company, develops treatments for rare and life-threatening genetic diseases. The company focuses on developing gene therapy product candidates for the treatment of type 1 spinal muscular atrophy, an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weaknes...</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=AveXis,_Inc.&amp;diff=408279&amp;oldid=prev"/>
		<updated>2024-09-18T13:40:36Z</updated>

		<summary type="html">&lt;p&gt;Pagină nouă: Pagina dedicata companiei AveXis, Inc. listata cu simbolul US.AVXS  ==Descriere companie== Novartis Gene Therapies, Inc. (https://www.novartis.com/), a gene therapy biotech company, develops treatments for rare and life-threatening genetic diseases. The company focuses on developing gene therapy product candidates for the treatment of type 1 spinal muscular atrophy, an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weaknes...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Pagină nouă&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Pagina dedicata companiei AveXis, Inc. listata cu simbolul US.AVXS&lt;br /&gt;
&lt;br /&gt;
==Descriere companie==&lt;br /&gt;
Novartis Gene Therapies, Inc. (https://www.novartis.com/), a gene therapy biotech company, develops treatments for rare and life-threatening genetic diseases. The company focuses on developing gene therapy product candidates for the treatment of type 1 spinal muscular atrophy, an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weakness. It offers AVXS-101, a AveXis’ gene therapy for the treatment of spinal muscular atrophy SMA Type 1, which is in Phase 1 clinical trial. Novartis Gene Therapies, Inc. was formerly known as AveXis, Inc., and changed its name in September 2020. The company was founded in 2010 and is based in Bannockburn, Illinois. AveXis, Inc. operates as a subsidiary of Novartis AG.&lt;br /&gt;
&lt;br /&gt;
==Grafic actiuni companie==&lt;br /&gt;
&amp;lt;iframe key=&amp;quot;tradeville&amp;quot; path=&amp;quot;graficSimbol/US.AVXS&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Ultimele stiri despre AveXis, Inc. (US.AVXS)==&lt;br /&gt;
&amp;lt;dynamicpagelist&amp;gt;&lt;br /&gt;
category=US.AVXS&lt;br /&gt;
count=10&lt;br /&gt;
order=descending&lt;br /&gt;
addfirstcategorydate=false&lt;br /&gt;
&amp;lt;/dynamicpagelist&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Categorie:US.AVXS]][[Categorie:Stiri despre companii]]&lt;/div&gt;</summary>
		<author><name>Admin</name></author>
	</entry>
</feed>